Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Rabbit Angiopoietin-2 Protein, His Tag (Cat. No. AN2-R52H4) captured on CM5 chip via anti-His antibody can bind Human TIE2, Fc Tag (Cat. No. TI2-H5255) with an affinity constant of 43.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Faricimab | RG-7716; RO-6867461 | Approved | F. Hoffmann-La Roche Ltd, Genentech Inc | Vabysmo | EU | Wet Macular Degeneration; Diabetes Complications; Macular Edema | Roche Registration Gmbh | 2022-01-28 | Macular Edema; Choroid Diseases; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Complications; Diabetic Retinopathy; Diabetes Mellitus; Retinal Vein Occlusion; Macular Degeneration; Choroidal Neovascularization | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| RG-6120 | RG-6120 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Macular Degeneration | Details |
| RO-7250284 | RO-7250284 | F. Hoffmann-La Roche Ltd | Details | ||
| MEDI-3617 | ANG-2-mAb; MEDI-3617; Anti-ANG-2-mAb | Medimmune | Details | ||
| PF-5057459 | CVX-241; CovX-241; PF-05057459 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| Zansecimab | LY-3127804 | Eli Lilly And Company | Details | ||
| IBI-324 | IBI-324 | Phase 1 Clinical | Innovent Biologics (Usa), Inc | Diabetic macular oedema | Details |
| ASKG-712 | AM-712; ASKG-712 | Phase 1 Clinical | Wet Macular Degeneration; Macular Degeneration | Details | |
| Vanucizumab | RG-7221; RO-5520985; B800Z06O8K (UNII code) | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms; Colorectal Neoplasms | Details |
| Trebananib | AMG-386; 20060439 | Phase 2 Clinical | Amgen Inc, Takeda Pharmaceutical Co Ltd | Fallopian Tube Neoplasms; Breast Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Sarcoma; Peritoneal Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Gliosarcoma; Endometrial Neoplasms; Carcinoma, Adenosquamous; Lung Neoplasms; Uterine Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Monocytic, Acute; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Gastrointestinal Neoplasms; Neoplasms; Solid tumours; Leukemia, Myeloid; Leukemia, Erythroblastic, Acute; Carcinoma; Carcinoma, Renal Cell; Rectal Neoplasms; Hemangiosarcoma; Colonic Neoplasms; Ovarian Neoplasms; Kidney Diseases; Leukemia, Myelomonocytic, Acute; Glioblastoma; Sarcoma, Endometrial Stromal; Central Nervous System Neoplasms; Neuroendocrine Tumors; Leukemia, Megakaryoblastic, Acute; Oligodendroglioma | Details |
| BI-836880 | BI-836880 | Phase 2 Clinical | Ablynx Nv | Neoplasms; Wet Macular Degeneration | Details |
This web search service is supported by Google Inc.
A-Z
